Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has disclosed its position regarding Avadel Pharmaceuticals plc under Rule 8.3 of the Irish Takeover Panel Act. As of January 6, 2026, Vanguard holds 5,863,443 ordinary shares, which represents a 6.02% interest in Avadel's securities. This disclosure is a part of the standard regulatory requirements for parties with interests exceeding 1% in relevant securities.

The filing also reflects recent transactions, including the purchase of 1,292 shares and the sale of 285 shares, both at a price of 21.50 USD per share. There are no notable dealings in cash-settled or stock-settled derivatives associated with Avadel's securities by Vanguard at this time. Furthermore, no indemnity or option arrangements exist between Vanguard and any parties associated with Avadel's offer.